Testing aimed at detecting the co-deletion of chromosomes 1p and 19q and IDH mutation is one of the main genetic approaches to glioma diagnosis, as it enables the differentiation of oligodendriogliomas from astrocytomas [2,5]. This evidence concerns the gene IDH2 and central nervous system cancer.